©2014 Baishideng Publishing Group Inc.
World J Gastrointest Pharmacol Ther. Aug 6, 2014; 5(3): 156-168
Published online Aug 6, 2014. doi: 10.4292/wjgpt.v5.i3.156
Published online Aug 6, 2014. doi: 10.4292/wjgpt.v5.i3.156
Table 5 Recomendations for management of patients with cirrhosis
| First line therapy | |
| Recognize and withdraw all causes of acute kidney disease | |
| Resolve primary liver disease | |
| Encounter hypoalbuminemia with albumin infusion and tension ascites with repeated paracentesis plus albumin | |
| Have a high level of suspicion and treat spontaneous bacterial peritonitis | |
| Be vigilant and have into close monitoring patients win acute kidney injury network stage 1 and sCr > 1.5 mg/dL (133 μmol/L) or initial acute kidney injury network stage > 1 | |
| If there is no improvement within 2 d, proceed to specific treatment measures | |
| Second line therapy | |
| Patients hospitalized at the ward | If the diagnosis of hepatorenal syndrome has been placed: |
| Give albumin and terlipressin in continuous infusion | |
| If there is improvement within 4 d continue with oral midrodrine | |
| When terlipressin is unavailable: | |
| Give midrodrine plus octreotide plus albumin | |
| Patients admitted to intensive care unit | Norepinephrine plus albumin |
| Third line therapy | |
| Patients who qualify for transplant | Consider liver or simultaneous liver kidney transplantation |
| Give therapeutic bridges – Dialysis, transjugular intrahepatic portosystemic shunt | |
| Patients who do not qualify for transplant | Continue the combination of terlipressin plus albumin |
| Dialysis, TIPS | |
- Citation: Pipili C, Cholongitas E. Renal dysfunction in patients with cirrhosis: Where do we stand? World J Gastrointest Pharmacol Ther 2014; 5(3): 156-168
- URL: https://www.wjgnet.com/2150-5349/full/v5/i3/156.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v5.i3.156